Absorbable biomaterial developer Metabolix said it amended its license agreement with medical device company Tepha, forgoing future royalties and providing 2 additional Metabolix production strains and related IP in exchange for a $2 million lump sum.
Read the full story at our sister site, Medical Design & Outsourcing.